Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1997-11-13
1999-11-09
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
530380, 530381, 530382, 530303, 530384, 514822, A61L 914, A61L 2500, A61L 1558
Patent
active
059808667
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an adhesive for tissue, which is to be used in the form of a two-pack type preparation and which is suitable for the uniform application of the adhesive at a concentration higher than that of an ordinary adhesive. In particular, the present invention relates to an adhesive for tissue (hereinafter referred to as tissue adhesive) suitable for the use in a method wherein a protein solution containing fibrinogen as the essential component and a thrombin solution are sprayed and also suitable for lowering the volume ratio of a thrombin solution to a fibrinogen solution of a high concentration so as to uniformly form fibrin of a high-concentration, whereby obtaining a high closing effect.
BACKGROUND OF THE INVENTION
Fibrinogen is a clotting factor having a very important role in the final stage of the so-called blood-coagulation cascade. In the activation of, for example, the blood clotting system after a damage, soluble fibrinogen is converted, by thrombin, into insoluble fibrin which has an important role of contributing to the hemostasis and curing of a wound. Recently, a tissue adhesive was developed taking advantage of this theory in the final phase of the blood clotting, and it is now used as an adhesive in place of a suture of a soft organ such as liver or spleen or as a suture assistant in a surgical operation. A tissue adhesive is widely used also in other clinical situation.
For the application of the tissue adhesive to an affected part of the body, a "sequential method" wherein a fibrinogen solution and a thrombin solution are applied alternately to form a laminate coat or a "simultaneous method" wherein both the fibrinogen solution and thrombin solution are applied simultaneously to mix them together was mainly employed. However, the sequential method has a problem in that a major part of the fibrinogen solution flows down prior to the formation of a fibrin gel, and also the simultaneous method has a problem in that the formed fibrin gel is heterogeneous. Therefore, the effect of the tissue adhesive was limited in both the sequential method and simutaneous method.
Recently, a spray method has just started to be spread for solving the above-described problems. In this method, a fibrinogen solution and a thrombin solution in each syringe are simultaneously ejected together with a sterile gas to spray these two solutions in the form of a mist mixture. A preferred example of the devices for this method is described in International Patent Publication (PCT WO94-07420). However, even such a spray method has a problem to be solved for obtaining a complete effect of the tissue adhesive when a strong adhesion and closing effect are demanded in, for example, the treatment of great vessels and also the treatment of air leak in the lungs.
Investigations were made for improving the effect of the tissue adhesive by increasing the concentration of fibrinogen to find that, although the clotting strength and adhesive power of the fibrin gel obtained by the sequantial method are increased as the final concentration of fibrinogen in the mixture of the two components is increased, they are no more increased even when the final concentration of fibrinogen is increased to about 4% or higher [see "Kiso to Rinsho" (Basic and Clinical Report), 20, 2399 to 2405 (1986), and 23, 3735 to 3743 (1989)]. However, when the sequential method is employed, the fibrin gel obtained by such a test cannot be uniformly applied. Thus, it cannot be said that the advantage of the increase in the final concentration of fibrinogen has been put to practical use.
Japanese Patent Unexamined Published Application (hereinafter referred to as "J. P. KOKAI") No. Sho 61-293443 discloses a method for increasing the final concentration of fibrinogen in the mixture of the two components by changing the mixing ratio of the fibrinogen solution to the thrombin solution in its specification (in particular, in the "test results" in the detailed description of the Invention). In this specifica
REFERENCES:
patent: 4427651 (1984-01-01), Stroetmann
patent: 4983386 (1991-01-01), Kamishita et al.
patent: 5030215 (1991-07-01), Morse et al.
patent: 5461081 (1995-10-01), Ali et al.
patent: 5582596 (1996-12-01), Fukunaga et al.
Kiso to Rinsho (Basic and Clinical Report), vol. 20, No. 4, pp. 2399-2405, ar. 1986.
Hiroshi Kaetsu, et al., The Clinical Report, vol. 23, No. 10, pp. 3735-3743, "Studies on the Optimal Compounding Ratio of Fibrin Adhesive", Jul. 1989.
Fukunaga Nobuto
Kaetsu Hiroshi
Sakamoto Takahiro
Shinya Noriko
Uchida Takanori
Channavajjala Lakshmi
Juridical Foundation The Chemosero-Therapeutic Research Institut
Page Thurman K.
LandOfFree
Tissue adhesive suitable for spray application does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue adhesive suitable for spray application, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue adhesive suitable for spray application will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1451677